Travelan® Progresses to Phase 3 Trials: Positive Results Show Promise

Immuron Limited (ASX: IMC) advances Travelan® to Phase 3 trials with FDA support, based on successful Phase 2 results. Administered once daily, Travelan® demonstrated efficacy against ETEC-induced diarrhea, with a 36.4% reduction in moderate to severe cases compared to placebo. Additionally, Travelan® showed a 66.7% reduction in severe diarrhea and an 83.3% decrease in early antibiotic treatment requirement. Notably, all subjects needing IV fluids were in the placebo group.

Despite a lower-than-expected attack rate, the study proved Travelan® 's efficacy. Immuron plans Phase 3 trials and FDA discussions for Travelan®'s prophylactic use against Travelers’ Diarrhea. These findings underscore Travelan®'s potential as a preventive measure against infectious enteric diseases, particularly significant for the US military. Further research will explore optimal dosing regimens.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com